Wouldnt it be wonderful if the products that are manufactured, have such great demand that, they fly off the shelves?
Our
assessment of the drug shortage list in U.S. and Canada provides a list of opportunities,
which are an outcome of shortage of the active pharmaceutical ingredient (API).
While
manufacturers struggle with ideas, we list opportunities that pharmaceutical
companies can capitalize upon.
Not all shortages are an outcome of manufacturing delays or quality problems; the growing demand for some products (especially injections) and lack of API supply of others is something that, if addressed, can become a potential windfall for companies (Read Forbes Millions to be made onGeneric Drugs?).
Old, established active ingredients, with
limited supply options are usually the ones which have been driven to shortage. Utilizing the Pharma Compass database, a comprehensive list of existing and alternate supply options was prepared to assist the industry get started
Product
Dosage Form
Active DMFs
Other potential suppliers
Trimipramine Maleate
Capsule
Sanofi-Aventis
Lundbeck
R. L. Fine Chem
Tiopronin
Tablet
Okami Chemical Industry
Methylphenidate HCl
Tablet, capsule
Cambrex,Charles City
Chattem Chemicals
Euticals inc
Johnson Matthey
Mallinckrodt
Noramco inc
Rhodes Technologies Inc
Siegfried USA
AbbVie
BASF Pharma
Centaur Pharmaceuticals
CF Pharma
Harman Finochem
Janssen Pharmaceutica
Macfarlan-Smith
SCI Pharmtech
Sun pharmaceutical
Fluoxymesterone(Androxy)
Tablet
Cedarburg Pharmaceuticals Inc
Acetohydroxamic Acid
Tablet
Isochem Sa
Methyldopate HCl
Injectable
Seratec
Fomepizole
Injectable
Apicore US LLC
Cambridge Major Labs
Navinta LLC
Seratec
Strem Chemicals
Boehringer Ingelheim facilities in St.
Petersberg, Virginia, while listed have been excluded from the list on account
of them shutting down the facility and subsequent plans
of re-starting it not materializing.
Preventing drug shortages is a key focus
area for the USFDA and Health Canada. For this reason, not only do the regulatory
agencies have websites which lists all the shortages, but the USFDA has also developed their own mobile app to address concerns of all the
stakeholders.
Addressing drug shortages is smart business
since it ensures product availability, affordability and assurance along with
profitability for the industry.
Share